Precision BioLogic Inc. presented MNBA data at the World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, Scotland, May 20–24. Recognizing the need to improve factor VIII (FVIII ) inhibitor testing for people with hemophilia A, the company studied the agreement between a chromogenic modified Nijmegen-Bethesda assay (MNBA) and a qualitative ELISA test in the detection of FVIII inhibitors in plasma samples.
Posts - Factor Assays
Jun 7, 2018 1:04pm
Jun 29, 2017 7:38am
Dr. Ali Sadeghi-Khomami, Precision BioLogic Inc., provided these in-depth technical questions about the Nijmegen Bethesda Assay (NBA), which we use to quantitate specific factor inhibitors such as anti-factor VIII or anti-factor IX. George forwarded his questions to Connie Miller and Amanda Payne, US Centers for Disease Control and Prevention (CDC ) who have been working on NBA accuracy and precision upgrades for several years. Here are Dr. Ali's questions and answers provided by Drs. Miller and Payne; thanks to all for your support.
Jun 6, 2017 10:52am
George occasionally receives questions about factor substitution assays. We coagulationists of a "certain age" can recall preparing barium sulfate or aluminum hydroxide "adsorbed" plasma, aged plasma, and serum, then performing mixing studies on prolonged PTT patient plasmas. We mixed the patient plasma 1:1 with pooled normal plasma and the adsorbed and aged plasma and serum,